Paclitaxel-coated devices linked to late mortality in PAD treatment

The use of paclitaxel-coated balloons and stents in the femoropopliteal arteries of patients with peripheral artery disease (PAD) was associated with relative mortality increases of 68 percent and 93 percent at two and five years of follow-up, respectively, according to a meta-analysis published Dec. 6 in the Journal of the American Heart Association.

Gene editing process leads to personalized advice for heart patient

University of Pennsylvania researchers have developed a stem cell-based test to determine whether genetic variants in heart muscle cells are benign or pathogenic. In other words, they’ve added some certainty to variants of uncertain significance—the tricky alleles that can either contribute to the development of diseases or be completely harmless.

Study: SAVR mortality predicts TAVR outcomes in US hospitals

Hospitals with favorable outcomes for surgical aortic valve replacement (SAVR) procedures subsequently see better transcatheter aortic valve replacement (TAVR) outcomes when they launch TAVR programs, researchers reported in JAMA Cardiology Dec. 5, suggesting the quality of an institution’s surgical team could be an indicator of how they’ll fare after they initiate TAVR.

Medtronic Named One of America's Best Corporate Citizens in 2018 by Forbes Magazine

DUBLIN — December 10, 2018 — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has been named one of America's Most JUST Companies in 2018, according to Forbes magazine and JUST Capital, a nonprofit that ranks publicly-traded corporations on the issues Americans care about most.